Latest News

 Filter by Provider

Lam Research is a semiconductor machine business that’s breaking records, but its stock price has been cut nearly in half from highs in 2026. Is it a good stock to buy right now?

Operating margins are expected to reach the high end of management's long-term range despite component disruptions and rising costs.

Dealer channel relief and a China plant feeding non-U.S. markets could reshape XPEL's margins, but both depend on a 2027 rollout.

IonQ's stock has had a rough year, but a turnaround could be coming.

Arcutis Biotherapeutics (NASDAQ:ARQT) raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand. The company reported $143.9 million in third-quarter net product revenue, up 11% f

Enerpac Tool Group (NYSE:EPAC) outlined a plan to grow organic revenue faster than its markets through fiscal 2030, while integrating its newly acquired SFE fabrication tools business and expanding profit margins. At its 2026 Investor Day, the company introduced a growth strategy called PROPEL and

Cirrus Logic (NASDAQ:CRUS) reported fiscal second-quarter revenue of $559.5 million, up 22% from the prior quarter, as higher smartphone volumes and increased content per device helped offset weaker PC and general-market sales. The chipmaker forecast revenue of $510 million to $570 million for the

AppLovin (NASDAQ:APP) reported record third-quarter 2026 revenue of $2.18 billion, up 55% from a year earlier, as improvements to its advertising models helped drive growth in mobile gaming and consumer advertising. Both revenue and adjusted EBITDA exceeded the high end of the company’s guidance. C

Billiontoone (NASDAQ:BLLN) raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also reported its fifth consecutive quarter of positive GAAP operating income. Revenue fo

Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development. The company reported total revenue of

ARKO Petroleum reported higher third-quarter earnings and raised its full-year adjusted EBITDA outlook, as stronger fuel margins offset lower sales volumes and the company worked toward closing an acquisition in the fourth quarter. Net income rose to $13.3 million from $10.1 million a year earlier.

Alto Ingredients (NASDAQ:ALTO) reported a fifth consecutive quarter of positive gross profit, operating income, net income and adjusted EBITDA, while raising its expectations for 2026 clean fuel tax credit earnings. On its Nov. 4 earnings call, the producer of specialty alcohols, renewable fuel and

Ascent Industries (NASDAQ:ACNT) reported higher third-quarter sales and adjusted earnings as organic growth and its Midwest Graphic Sales acquisition helped lift revenue, though executives cautioned that seasonal product demand would compress margins in the fourth quarter. Third-quarter net sales r

A Democratic sweep might be just the medicine Google needs to prosper.

CLO debt reset cut financing costs while extending the reinvestment period.

Considering its strong third-quarter results, substantial order backlog, healthy growth prospects, and consistent dividend payments, Toromont could be an attractive buying opportunity for long-term investors.